Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses.

Rolland A, Jouvin-Marche E, Viret C, Faure M, Perron H, Marche PN.

J Immunol. 2006 Jun 15;176(12):7636-44.

2.

Correlation between disease severity and in vitro cytokine production mediated by MSRV (multiple sclerosis associated retroviral element) envelope protein in patients with multiple sclerosis.

Rolland A, Jouvin-Marche E, Saresella M, Ferrante P, Cavaretta R, Créange A, Marche P, Perron H.

J Neuroimmunol. 2005 Mar;160(1-2):195-203. Epub 2004 Dec 8.

PMID:
15710473
3.

Multiple sclerosis retrovirus particles and recombinant envelope trigger an abnormal immune response in vitro, by inducing polyclonal Vbeta16 T-lymphocyte activation.

Perron H, Jouvin-Marche E, Michel M, Ounanian-Paraz A, Camelo S, Dumon A, Jolivet-Reynaud C, Marcel F, Souillet Y, Borel E, Gebuhrer L, Santoro L, Marcel S, Seigneurin JM, Marche PN, Lafon M.

Virology. 2001 Sep 1;287(2):321-32.

4.

Endogenous retroviral genes, Herpesviruses and gender in Multiple Sclerosis.

Perron H, Bernard C, Bertrand JB, Lang AB, Popa I, Sanhadji K, Portoukalian J.

J Neurol Sci. 2009 Nov 15;286(1-2):65-72. doi: 10.1016/j.jns.2009.04.034. Epub 2009 May 17. Review.

PMID:
19447411
5.

Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein.

Curtin F, Perron H, Kromminga A, Porchet H, Lang AB.

MAbs. 2015;7(1):265-75. doi: 10.4161/19420862.2014.985021.

6.

HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection.

Fanales-Belasio E, Moretti S, Fiorelli V, Tripiciano A, Pavone Cossut MR, Scoglio A, Collacchi B, Nappi F, Macchia I, Bellino S, Francavilla V, Caputo A, Barillari G, Magnani M, Laguardia ME, Cafaro A, Titti F, Monini P, Ensoli F, Ensoli B.

J Immunol. 2009 Mar 1;182(5):2888-97. doi: 10.4049/jimmunol.0711406.

7.

Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-associated retrovirus/HERV-W endogenous retrovirus, but not Human herpesvirus 6.

Mameli G, Astone V, Arru G, Marconi S, Lovato L, Serra C, Sotgiu S, Bonetti B, Dolei A.

J Gen Virol. 2007 Jan;88(Pt 1):264-74.

PMID:
17170460
8.

Polybacterial immunomodulator Respivax restores the inductive function of innate immunity in patients with recurrent respiratory infections.

Nikolova M, Stankulova D, Taskov H, Nenkov P, Maximov V, Petrunov B.

Int Immunopharmacol. 2009 Apr;9(4):425-32. doi: 10.1016/j.intimp.2009.01.004. Epub 2009 Jan 30.

PMID:
19186221
9.

TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses.

Iwamoto S, Iwai S, Tsujiyama K, Kurahashi C, Takeshita K, Naoe M, Masunaga A, Ogawa Y, Oguchi K, Miyazaki A.

J Immunol. 2007 Aug 1;179(3):1449-57.

10.

MSRV envelope protein is a potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GNbAC1 in multiple sclerosis treatment.

Madeira A, Burgelin I, Perron H, Curtin F, Lang AB, Faucard R.

J Neuroimmunol. 2016 Feb 15;291:29-38. doi: 10.1016/j.jneuroim.2015.12.006. Epub 2015 Dec 11.

11.

Inflammatory response of endothelial cells to a human endogenous retrovirus associated with multiple sclerosis is mediated by TLR4.

Duperray A, Barbe D, Raguenez G, Weksler BB, Romero IA, Couraud PO, Perron H, Marche PN.

Int Immunol. 2015 Nov;27(11):545-53. doi: 10.1093/intimm/dxv025. Epub 2015 May 8.

12.

Synergistic immune responses induced by endogenous retrovirus and herpesvirus antigens result in increased production of inflammatory cytokines in multiple sclerosis patients.

Brudek T, Christensen T, Hansen HJ, Petersen T, Møller-Larsen A.

Scand J Immunol. 2008 Mar;67(3):295-303. doi: 10.1111/j.1365-3083.2007.02067.x. Erratum in: Scand J Immunol. 2008 Apr;67(4):422.

13.

Molecular cloning and characterization of MSRV-related sequences associated with retrovirus-like particles.

Komurian-Pradel F, Paranhos-Baccala G, Bedin F, Ounanian-Paraz A, Sodoyer M, Ott C, Rajoharison A, Garcia E, Mallet F, Mandrand B, Perron H.

Virology. 1999 Jul 20;260(1):1-9.

14.

Analysis of transcribed human endogenous retrovirus W env loci clarifies the origin of multiple sclerosis-associated retrovirus env sequences.

Laufer G, Mayer J, Mueller BF, Mueller-Lantzsch N, Ruprecht K.

Retrovirology. 2009 Apr 15;6:37. doi: 10.1186/1742-4690-6-37.

15.

Multiple sclerosis-associated retroviral agent (MSRV)-stimulated cytokine production in patients with relapsing-remitting multiple sclerosis.

Saresella M, Rolland A, Marventano I, Cavarretta R, Caputo D, Marche P, Perron H, Clerici M.

Mult Scler. 2009 Apr;15(4):443-7. doi: 10.1177/1352458508100840. Epub 2009 Feb 27.

PMID:
19251836
16.

Respiratory syncytial virus induced type I IFN production by pDC is regulated by RSV-infected airway epithelial cells, RSV-exposed monocytes and virus specific antibodies.

Schijf MA, Lukens MV, Kruijsen D, van Uden NO, Garssen J, Coenjaerts FE, Van't Land B, van Bleek GM.

PLoS One. 2013 Nov 26;8(11):e81695. doi: 10.1371/journal.pone.0081695. eCollection 2013.

17.

Combined TLR2 and TLR4 ligation in the context of bacterial or helminth extracts in human monocyte derived dendritic cells: molecular correlates for Th1/Th2 polarization.

van Riet E, Everts B, Retra K, Phylipsen M, van Hellemond JJ, Tielens AG, van der Kleij D, Hartgers FC, Yazdanbakhsh M.

BMC Immunol. 2009 Feb 4;10:9. doi: 10.1186/1471-2172-10-9.

18.

Lack of immune responses against multiple sclerosis-associated retrovirus/human endogenous retrovirus W in patients with multiple sclerosis.

Ruprecht K, Gronen F, Sauter M, Best B, Rieckmann P, Mueller-Lantzsch N.

J Neurovirol. 2008 Apr;14(2):143-51. doi: 10.1080/13550280801958922.

PMID:
18444086
19.

GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.

Curtin F, Lang AB, Perron H, Laumonier M, Vidal V, Porchet HC, Hartung HP.

Clin Ther. 2012 Dec;34(12):2268-78. doi: 10.1016/j.clinthera.2012.11.006. Epub 2012 Nov 29.

PMID:
23200102
20.

Human cathelicidin peptide LL-37 modulates the effects of IFN-gamma on APCs.

Nijnik A, Pistolic J, Wyatt A, Tam S, Hancock RE.

J Immunol. 2009 Nov 1;183(9):5788-98. doi: 10.4049/jimmunol.0901491. Epub 2009 Oct 7.

Supplemental Content

Support Center